Takara Bio Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TKBIF research report →
Companywww.takara-bio.com
Takara Bio Inc. , together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names.
- CEO
- Tsuyoshi Miyamura
- IPO
- 2020
- Employees
- 1,838
- HQ
- Kusatsu, JP
Price Chart
Valuation
- Market Cap
- $879.03M
- P/E
- -14.35
- P/S
- 3.42
- P/B
- 1.33
- EV/EBITDA
- -41.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.25%
- Op Margin
- -11.63%
- Net Margin
- -23.81%
- ROE
- -9.22%
- ROIC
- -3.72%
Performance & Tape
- 52W High
- $23.20
- 52W Low
- $5.00
- 50D MA
- $7.30
- 200D MA
- $15.73
- Beta
- 0.44
- Avg Volume
- 87.415
Get TickerSpark's AI analysis on TKBIF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TKBIF Coverage
We haven't published any research on TKBIF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TKBIF Report →